Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Hematopoietic Growth Factors

How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

Bone Marrow Transplantation volume 33, pages 715–719 (2004)Cite this article

Summary:

Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ⩾0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P=0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P=0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Schmitz N, Dreger P, Zander AR et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261–266.

    CAS  Google Scholar 

  2. Gorin NC, Coiffier B, Hayat M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80: 1149–1157.

    CAS  PubMed  Google Scholar 

  3. Torres-Gomez A, Jimenez MA, Alvarez MA et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995; 71: 65–70.

    Article  CAS  Google Scholar 

  4. Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533–536.

    CAS  Google Scholar 

  5. Stahel RA, Jost LM, Honegger H et al. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997; 15: 1730–1735.

    Article  CAS  Google Scholar 

  6. Bolwell B, Goormastic M, Dannley R et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19: 215–219.

    Article  CAS  Google Scholar 

  7. Bolwell BJ, Pohlman B, Andresen S et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369–373.

    Article  CAS  Google Scholar 

  8. Ali MY, Oyama Y, Monreal J et al. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 109/L neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant 2002; 30: 749–752.

    Article  CAS  Google Scholar 

  9. Rihn C, Cilley F, Monreal J et al. Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Blood 2002; 100: 417a–418a, (abstract #1618).

    Google Scholar 

  10. Ali MY, Oyama Y, Monreal J et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861–864.

    Article  CAS  Google Scholar 

  11. Spitzer TR . Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893–898.

    Article  CAS  Google Scholar 

  12. San Miguel JF, Hernandez MD, Gonzalez M et al. A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation. Br J Haematol 1996; 94: 140–147.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Auxiliary Board of the Northwestern Memorial Hospital.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Hematopoietic Stem Cell Transplant Program, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

    A Verma, J Pedicano, S Trifilio, S Singhal, M Tallman, J Winter, S Williams, L Gordon, J Monreal & J Mehta

Authors
  1. A Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Pedicano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Trifilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Monreal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verma, A., Pedicano, J., Trifilio, S. et al. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?. Bone Marrow Transplant 33, 715–719 (2004). https://doi.org/10.1038/sj.bmt.1704415

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704415

Keywords

This article is cited by

Search

Advanced search

Quick links